Alkermes plc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Alkermes plc is a biopharmaceutical company that develops and commercializes medicines for central nervous system disorders, including schizophrenia, bipolar disorder, opioid dependence, and alcohol dependence. It also earns royalties from products using its drug-delivery technologies licensed to other pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | $423K | 9,000at $46.99 | Sep 1, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ALKS activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.